Status:
UNKNOWN
Infranodal Conduction Time During TAVR as Predictor of HAVB
Lead Sponsor:
University Hospital, Saarland
Conditions:
Severe Aortic Valve Stenosis
High-degree AV Block
Eligibility:
All Genders
Phase:
NA
Brief Summary
Consecutive patients with high grade aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) with a self-expanding valve (Medtronic CoreValve Evolut R® or Edwards Sapien S3®) without ...
Eligibility Criteria
Inclusion
- Indication for TAVR according to current guidelines
- Written informed consent
Exclusion
- 1\. Pre-existent intracardiac device as pacemaker, implanted cardioverter defibrillator or CRT-P/CRT-D device
Key Trial Info
Start Date :
June 21 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04128384
Start Date
June 21 2018
End Date
January 31 2023
Last Update
October 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum des Saarlandes
Homburg, Saarland, Germany, 66421